Bridgewater Associates LP Decreases Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Bridgewater Associates LP reduced its stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 52.4% during the third quarter, according to its most recent filing with the SEC. The fund owned 32,881 shares of the company's stock after selling 36,167 shares during the quarter. Bridgewater Associates LP's holdings in Pediatrix Medical Group were worth $381,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Quest Partners LLC increased its stake in shares of Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company's stock worth $35,000 after purchasing an additional 622 shares in the last quarter. nVerses Capital LLC bought a new stake in Pediatrix Medical Group during the 2nd quarter valued at $31,000. Innealta Capital LLC bought a new stake in Pediatrix Medical Group during the 2nd quarter valued at $33,000. Nisa Investment Advisors LLC lifted its position in shares of Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock worth $36,000 after acquiring an additional 1,524 shares in the last quarter. Finally, CWM LLC boosted its holdings in shares of Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company's stock worth $74,000 after acquiring an additional 3,681 shares during the period. 97.71% of the stock is owned by institutional investors.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of the firm's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark S. Ordan sold 27,600 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares in the company, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Pediatrix Medical Group Price Performance

NYSE:MD traded down $0.19 during mid-day trading on Tuesday, reaching $14.82. The stock had a trading volume of 499,789 shares, compared to its average volume of 860,672. The firm has a 50 day moving average price of $13.42 and a two-hundred day moving average price of $10.33. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. Pediatrix Medical Group, Inc. has a one year low of $6.62 and a one year high of $16.41.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the firm earned $0.29 EPS. The firm's quarterly revenue was up .9% compared to the same quarter last year. On average, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MD has been the topic of a number of analyst reports. Truist Financial upped their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a report on Monday, November 4th. StockNews.com downgraded Pediatrix Medical Group from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Mizuho raised their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a report on Tuesday, November 19th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $16.10.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.